Bavarian Nordic Recruits US Firm For Packaging Services For Its Monkeypox Vaccine

  • Bavarian Nordic A/S BVNRY signed up a U.S.-based manufacturer to fill and finish its Jynneos monkeypox vaccine, and the production is expected to begin later this year.
  • The company aims to finish the technology transfer in three months to Grand River Aseptic Manufacturing (GRAM), which usually takes nine months.
  • Over 13,500 cases of the disease have been reported in the U.S., with global cases of over 38,800.
  • Related: The Only Monkeypox Vaccine Maker Finds It Difficult To Meet Accelerating Demand.
  • The company said the agreement would significantly expand Bavarian Nordic's manufacturing capacity to benefit the U.S. and globally.
  • The company has already taken several steps to increase the filling capacity at its Danish manufacturing site, now operating double the capacity as before the monkeypox outbreak in May 2022, with an expectation to further increase over the coming months. 
  • In parallel, Bavarian Nordic is exploring additional partnerships to increase manufacturing capacity further to improve global vaccine access.
  • Bavarian Nordic received an additional order for 2.5 million vaccine doses from the U.S. Biomedical Advanced Research and Development Authority, which will be filled at GRAM.
  • Combined with previous orders, BARDA has requested a total of 5.5 million doses for delivery in 2022 and 2023.
  • To boost the supply of monkeypox vaccines, the U.S. is making an additional 1.8 million doses of the Jynneos vaccine available for orders.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsGeneralBriefsMonkeypox
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!